Genetic and epigenetic alterations of lysophosphatidic acid receptor genes in rodent tumors by experimental models

Journal of Toxicologic Pathology

Volumn 24, Issue 3, 2011, Pages 143-148

  Tsujiuchi, Toshifumi ^a   Okabe, Kyoko ^a   Fukushima, Nobuyuki ^a  

^a KINKI UNIVERSITY   (Japan)

Author keywords

DNA methylation; LPA; LPA receptor; Mutation; Rodent

Indexed keywords

G PROTEIN COUPLED RECEPTOR; LYSOPHOSPHATIDIC ACID RECEPTOR; LYSOPHOSPHATIDIC ACID RECEPTOR 1; LYSOPHOSPHATIDIC ACID RECEPTOR 2; LYSOPHOSPHATIDIC ACID RECEPTOR 3; LYSOPHOSPHATIDIC ACID RECEPTOR 4; LYSOPHOSPHATIDIC ACID RECEPTOR 5; LYSOPHOSPHATIDIC ACID RECEPTOR 6; UNCLASSIFIED DRUG;

ASCITES; CANCER CELL CULTURE; CARCINOGENESIS; DNA METHYLATION; GENE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE LOCATION; GENE MUTATION; GENETIC EPIGENESIS; GENETIC IDENTIFICATION; HUMAN; INTRACELLULAR SIGNALING; LIVER CARCINOMA; LUNG CARCINOMA; LYSOPHOSPHATIDIC ACID RECEPTOR 1 GENE; LYSOPHOSPHATIDIC ACID RECEPTOR 2 GENE; LYSOPHOSPHATIDIC ACID RECEPTOR 3 GENE; LYSOPHOSPHATIDIC ACID RECEPTOR 4 GENE; LYSOPHOSPHATIDIC ACID RECEPTOR 5 GENE; LYSOPHOSPHATIDIC ACID RECEPTOR 6 GENE; LYSOPHOSPHATIDIC ACID RECEPTOR GENE; MUTATIONAL ANALYSIS; NONHUMAN; OVARY CANCER; PANCREAS CARCINOMA; PROTEIN FUNCTION; RECEPTOR GENE; REVIEW;

EID: 83155172554     PISSN: 09149198     EISSN: None     Source Type: Journal    
DOI: 10.1293/tox.24.143     Document Type: Review

References (44)

1. Contos JJA, Ishii I, and Chun J. Lysophosphatidic acid receptors. Mol Pharmacol. 58: 1188-1196. 2000.
2. Aoki J, Inoue A, and Okudaira S. Two pathways for lysophosphatidic acid production. Biochim Biophys Acta. 1781: 513-518. 2008.
3. Ishii I, Fukushima N, Ye X, and Chun J. Lysophospholipid receptors: Signaling and biology. Annu Rev Biochem. 73: 321-354. 2004.
4. Lin M-E, Herr DR, and Chun J. Lysophosphatidic acid (LPA) receptors: Signaling properties and disease relevance. Prostaglandins Other Lipid Mediat. 91: 130-138. 2010.
5. Fang X, Schummer M, Mao M, Yu S, Tabassam FH, Swaby R, Hasegawa Y, Tanyi JL, LaPushin R, Eder A, Jaffe R, Erickson J, and Mills GB. Lysophosphatidic acid is a bioactive mediator in ovarian cancer. Biochim Biophys Acta. 1582: 257-264. 2002.
6. Furui T, LaPushin R, Mao M, Khan H, Watt SR, and Watt MAV. Overexpression of Edg-2/vzg-1 Induces apoptosis and anoikis in ovarian cancer cells in a lysophatidic acid-independent manner. Clinical Cancer Res. 5: 4308-4318. 1999.
7. Goetzl EJ, Dolezalova H, Kong Y, Hu YL, Jaffe RB, Kalli KR, and Conover CA. Distinctive expression and functions of the type 4 endothelial differentiation gene-encoded G protein-coupled receptor for lysophosphatidic acid in ovarian cancer. Cancer Res. 59: 5370-5375. 1999.
8. Shida D, Watanabe T, Aoki J, Hama K, Kitayama J, Sonoda H, Kishi Y, Yamaguchi H, Sasaki S, Sako A, Konishi T, Arai H, and Nagawa H. Aberrant expression of lysophosphatidic acid (LPA) receptors in human colorectal cancer. Lab Invest. 84: 1352-1362. 2004.
9. Schulte KM, Beyer A, Kohrer K, Oberhauser S, and Roher HD. Lysophosphatidic acid, a novel lipid growth factor for human thyroid cells: over-expression of the high-affinity receptor edg4 in differentiated thyroid cancer. Int J Cancer. 92: 249-256. 2001.
10. Yu S, Murph MM, Lu Y, Liu S, Hall HS, Liu J, Stephens C, Fang X, and Mills GB. Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells. J Natl Cancer Inst. 100: 1630-1642. 2008.
11. Tabata K, Baba K, Shiraishi A, Ito M, and Fujita N. The orphan GPCR GPR87 was deorphanized and shown to be a lysophosphatidic acid receptor. Biochem Biophys Res Commun. 363: 861-866. 2007.
12. Ishii I, Contos JJA, Fukushima N, and Chun J. Functional comparisons of the lysophosphatidic acid receptors, LPA1/VZG-1/EDG-2, LPA2/EDG-4, and LPA3/EDG-7 in neuronal cell lines using a retrovirus expression system. Mol Pharmacol. 58: 895-902. 2000.
13. Contos JJA, Ishii I, Fukushima N, Kingsbury MA, Ye X, Kawamura S, Brown JH, and Chun J. Characterization of lpa(2) (Edg4) and lpa(1)/lpa(2) (Edg2/Edg4) lysophosphatidic acid receptor knockout mice: signaling deficits without obvious phenotypic abnormality attributable to lpa(2). Mol Cell Biol. 22: 6921-6929. 2002.
14. Shimomura Y, Wajid M, Ishii Y, Shapiro L, Petukhowa L, Gordon D, and Christiano AM. Disruption of P2RY5, an orphan G protein-coupled receptor, underlies autosomal recessive woolly hair. Nature Genet. 40: 335-339. 2008.
15. Pasternack SM, von Kügelgen I, Aboud KAJ, Lee Y-A, Rüschendorf F, Voss K, Hillmer AM, Molderings GJ, Franz T, Ramirez A, Nürnberg P, Nöthen MM, and Berz RC. G protein-coupled receptor P2Y5 and its ligand LPA are involved in maintenance of human hair growth. Nature Genet. 40: 329-334. 2008.
16. Tsujino M, Fujii M, Okabe K, Mori T, Fukushima N, and Tsujiuchi T. Differential expressions and DNA methylation patterns of lysophosphatidic acid receptor genes in human colon cancer cells. Virchows Arch. 457: 669-676. 2010.
17. Okabe K, Hayashi M, Fujii M, Honoki K, Mori T, Fukushima N, and Tsujiuchi T. Mutations of lysophosphatidic acid receptor genes in human osteosarcoma cells. Pathobiology. 77: 278-282. 2010.
18. Konishi Y, Denda A, Kondo H, and Takahashi S. Lung carcinomas induced by oral administration of N-bis(2-hydroxypropyl)nitrosamine in rats. Gann. 67: 773-780. 1976.
19. Konishi Y, Kondoh H, Denda A, Takahashi S, and Inui S. Lung carcinomas induced by oral administration of N-bis(2- hydroxypropyl)nitrosamine in rats. In: Tumors of Early Llife in Man and Animals. Perugia Quadrennaial International Conference of Cancer. I Severi (ed.) Division of Cancer Resarch Perugia University, Perugia. 637-649. 1978.
20. Yamada T, Furukawa M, Hotta M, Yamasaki A, Honoki K, Fukushima N, and Tsujiuchi T. Mutations of lysophosphatidic acid receptor-1 gene during progression of lung tumors in rats. Biochem Biophys Res Commun. 378: 424-427. 2009.
21. Wakabayashi N, Tsujino M, Tajiri M, Taki M, Koshino A, Ikeda H, Fukushima N, and Tsujiuchi T. No mutations of lysophosphatidic acid receptor genes in lung adenocarcinomas induced by N-nitrosobis(2-hydroxypropyl)amine in rats. J Toxicol Pathol. 23: 63-66. 2010.
22. Ohashi K, Tsutsumi M, Tsujiuchi T, Kobitsu K, Okajima E, Nakajima Y, Nakano H, Takahashi M, Mori Y, and Konishi Y. Enhancement of N- nitrosodiethylamine-initiated hepatocarcinogenesis caused by a colchicines-induced cell cycle disturbance in partially hepatectomized rats. Cancer Res. 56: 3474-3479. 1996.
23. Tsutsumi M, Ohashi K, Tsujiuchi T, Kobayashi E, Kobitsu K, Kitada H, Majima T, Okajima E, Endoh T, Hasegawa K, Mori T, and Konishi Y. Disturbance of the cell cycle with colchicines enhances the growth advantage of diethylnitrosamine-induced hepatocytes in rats. Jpn J Cancer Res. 87: 5-9. 1996.
24. Nakae D, Yoshiji H, Mizumoto Y, Horiguchi K, Shiraiwa K, Tamura K, Denda A, and Konishi Y. High incidence of hepatocellular carcinomas induced by a choline deficient L-amino acid defined diet in rats. Cancer Res. 52: 5042-5045. 1992.
25. Obo Y, Yamada T, Furukawa M, Hotta M, Honoki K, Fukishima N, and Tsujiuchi T. Frequent mutations of lysophosphatidic acid receptor-1 gene in rat liver tumors. Mutat Res. 660: 47-50. 2009.
26. Mizumoto K, Tsutsumi M, Denda A, and Konishi Y. Rapid production of pancreatic carcinoma by initiation with N-nitrosobis(2-oxopropyl)amine and repeated augmentation pressure in hamsters. J Natl Cancer Inst. 80: 1564-1567. 1988.
27. Mizumoto K, Kitazawa S, Ito S, Takashima Y, Tsutsumi M, Denda A, and Konishi Y. Cycles of repeated augmentation pressure in rapid production of pancreatic and cholangiocellular carcinomas in hamsters initiated with N-nitrosobis(2-oxopropyl)amine. Carcinogenesis 10: 1457-1459. 1989.
28. Tsujiuchi T, Furukawa M, Yamasaki A, Hotta M, Kusunoki C, suyama N, Mori T, Honoki K, and Fukushima N. Infrequent mutation of lysophosphatidic acid receptor-1 gene in hamster pancreatic duct adenocarcinomas and established cell lines. J Toxicol Pathol. 22: 89-92. 2009.
29. Okabe K, Hayashi M, Yamawaki Y, Teranishi M, Honoki K, Mori T, Fukushima N, and Tsujiuchi T. Possible involvement of lysophosphatidic acid receptor-5 gene in the acquisition of growth advantage of rat tumor cells. Mol Carcinog. 2011; in press.
30. Sardar VM, Bautista DL, Fischer DJ, Yokoyama K, Nusser N, Viraq T, Wang DA, Baker DL, Tiqyi G, and Parrill AL. Molecular basis for lysophosphatidic acid receptor antagonist selectivity. Biochim Biophys Acta. 1582: 309-317. 2002.
31. Valentine WJ, Fells JI, Perygin DH, Mujahid S, Yokoyama K, Fujiwara Y, Tsukahara R, Van Brocklyn JR, Parrill AL, and Tiqyi G. Subtype-specific residues involved in ligand activation of the endothelial differentiation gene family lysophosphatidic acid receptors. J Biol Chem. 283: 12175-12187. 2008.
32. Kitada H, Tsutsumi M, Tsujiuchi T, Takahama M, Fukuda T, Narita N, and Konishi Y. Frequent mutations of Ki-ras but no mutations oh Ha-ras and p53 in lung lesions induced by N-nitrosobis(2-hydroxypropyl)amine in rats. Mol Carcinog. 15: 276-283. 1996.
33. Tsutsumi M, Murakami Y, Kondoh S, Tsujiuchi T, Honoki K, Horiguchi K, Noguchi O, Kobayashi E, Okita S, Sekiya T, and Konishi Y. Comparison of K-ras oncogene activation in pancreatic duct carcinomas and cholangiocarcinomas induced in hamsters by N-nitrosobis(2-oxopropyl)amine. Jpn J Cancer Res. 84: 956-960. 1993.
34. Malins DC, and Haimanot R. 4,6-Diamino-5-formamidopyrimidine, 8-hydroxyguanine and 8-hydroxyadenine in DNA from neoplastic liver of English sole exposed to carcinogens. Biochem Biophys Res Commun. 173: 614-619. 1990.
35. Moriya M, Ou C, Bodepudi V, Johnson F, Takeshita M, and Grollma AP. Site-specific mutagenesis using a gapped duplex vector: a study of translation synthesis past 8-oxodeoxyguanosine in E. coli. Mutat Res. 254: 281-288. 1991.
36. Kamiya H, Miura H, Murata-Kamiya N, Ishikawa H, Sakaguchi T, Inoue H, Sasaki T, Masutani C, Hanaoka F, and Nishimura S. 8-Hydroxyadenine (7,8-dihydro-8-oxoadenine) induces misincorporation in in vitro DNA synthesis and mutations in NIH3T3 cells. Nucleic Acids Res. 23: 2893-2899. 1995.
37. Wang D, Kreutzer DA, and Essigmann JM. Mutagenicity and repair of oxidative DNA damage: insights from studies using defined lesions. Mutat Res. 400: 99-115. 1998.
38. Nakae D, Yoshiji H, Maruyama H, Kinugasa T, Denda A, and Konishi Y. Production of both 8-hydroxydeoxyguanosine in liver DNA and γ-glutamyltransferase-positive hepatocellular lesions in rats given a choline-deficient, L-amino acid-defined diet. Jpn J Cancer Res. 81: 1081-1084. 1990.
39. Jones PA. DNA methylation and cancer. Oncogene. 21: 5358-5360. 2002.
40. Jones PA, and Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 3: 415-428. 2002.
41. Okabe K, Hayashi M, Yoshida I, Nishimura K, Fukushima N, and Tsujiuchi T. Distinct DNA methylation patterns of lysophosphatidic acid receptor genes during rat hepatocarcinogenesis induced by a choline deficient L-amino acid defined diet. Arch Toxicol. 2011; in press.
42. Tsujiuchi T, Shimizu K, Onishi M, Sugata E, Fujii H, Mori T, Honoki K, and Fukushima N. Involvement of aberrant DNA methylation on reduced expression of lysophosphatidic acid receptor-1 gene in rat tumor cell lines. Biochem Biophys Res Commun. 349: 1151-1155. 2006.
43. Okabe K, Hayashi M, Wakabayashi N, Yamawaki Y, Teranishi M, Fukushima N, and Tsujiuchi T. Different expressions and DNA methylation patterns of lysophosphatidic acid receptor genes in mouse tumor cells. Pathobiology. 77: 309-314. 2010.
44. Shano S, Hatanaka K, Ninose S, Moriyama R, Tsujiuchi T, and Fukushima N. A Lysophosphatidic acid receptor lacking the PDZ-binding domain is constitutively active and stimulates cell proliferation. Biochim Biophys Acta. 1783: 748-759. 2008.